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Sinusoidal Obstruction
Syndrome

Hepatic sinusoidal obstruction syndrome (SOS) is an obliterative venulitis of the terminal hepatic venules, which
in its more severe forms imparts a high risk of mortality. SOS, also known as veno-occlusive disease (VOD), occurs as a result of cytoreductive therapy prior to hematopoietic stem cell transplantation (HSCT), following
oxaliplatin-containing adjuvant or neoadjuvant chemotherapy for colorectal carcinoma metastatic to the liver
and treated by partial hepatectomy, in patients taking pyrrolizidine alkaloid-containing herbal remedies, and
in other particular settings such as the autosomal recessive condition of veno-occlusive disease with immunodeﬁciency (VODI). A central pathogenic event is toxic destruction of hepatic sinusoidal endothelial cells (SEC),
with sloughing and downstream occlusion of terminal hepatic venules. Contributing factors are SEC glutathione
depletion, nitric oxide depletion, increased intrahepatic expression of matrix metalloproteinases and vascular
endothelial growth factor (VEGF), and activation of clotting factors. The clinical presentation of SOS includes
jaundice, development of right upper-quadrant pain and tender hepatomegaly, ascites, and unexplained weight
gain. Owing to the potentially critical condition of these patients, transjugular biopsy may be the preferred route
for liver biopsy to exclude other potential causes of liver dysfunction and to establish a diagnosis of SOS. Treatment includes rigorous ﬂuid management so as to avoid excessive ﬂuid overload while avoiding too rapid
diuresis or pericentesis, potential use of pharmaceutics such as deﬁbrotide, coagulolytic agents, or methylprednisolone, and liver transplantation. Proposed strategies for prevention and prophylaxis include reducedintensity conditioning radiation for HSCT, treatment with ursodeoxycholic acid, and inclusion of bevacizumab
with oxaliplatin-based chemotherapeutic regimes. While signiﬁcant progress has been made in understanding
the pathogenesis of SOS and in mitigating against its adverse outcomes, this condition remains a serious complication of a selective group of medical treatments. ( J CLIN EXP HEPATOL 2014;4:332–346)
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bliterative endophlebitis in the terminal hepatic
veins of the human liver lobule was ﬁrst reported
by a pathologist from Prague in 1905, with the
only etiologic suggestion being syphilis.1 In 1954, terminal
vein lesions were described in Jamaican drinkers of bush
tea, characterized by obliteration of hepatic vein radicals
by varying amounts of subendothelial swelling and ﬁne
reticulated tissue.2 At later stages, a ﬁbrous pericentral
scar developed. In the early 1960's, studies of the effects
of ionizing radiation on mammalian tissues documented
that the hepatic vasculature could be damaged by this
mechanism,3 in the absence of antecedent vascular thrombosis.4,5 The most striking example of an obliterative
venous lesion induced by irradiation was documented in
humans with lung tumors receiving radiation treatment;
both the lung vasculature and that of the dome of the
liver that was included in the radiation ﬁeld developed
vascular obliteration, but not the remainder of the
unexposed liver.6 Shortly thereafter, induction of obliterative venopathy following heavy irradiation directly of
the human liver for metastatic disease was reported in 12
patients receiving upper abdominal irradiation by the
Stanford Linear Accelerator.7 Thus, by the mid-1960s, the
concept of hepatic veno-occlusive disease was well-established,
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PATHOGENESIS
Experimental Investigation in Animals
Initial experimental efforts to induce veno-occlusive disease
in animals focused on irradiation. Although the nonhuman primate liver is relatively resistant to radiationinduced veno-occlusive disease,25 veno-occlusive lesions
could be induced in primates26 and in non-primates27 by
exposure to chronic irradiation regimes. However, the underlying pathogenesis of this condition was not elucidated
with these early experimental models. Careful ultrastructural examination of human tissues suggested that the
initial morphologic change in hepatic veno-occlusive
disease was obstruction at the level of hepatic sinusoids,

Table 1 Causes of Sinusoidal Obstruction Syndrome (SOS).
Hematopoietic stem cell transplantation (HSCT)
Adjuvant or neoadjuvant chemotherapy with hepatectomy for
metastatic liver disease
Radiation-induced liver disease
Chemotherapy for acute myeloid leukemia (AML)
Liver transplantation
Use of herbal remedies
Veno-occlusive disease with immunodeﬁciency (VODI)

followed by obliteration of the terminal hepatic veins.28
This observation was conﬁrmed with the report in 1999
of a more economical and reproducible rodent model of
veno-occlusive disease.29 In rats gavaged with the pyrrolizidine alkaloid monocrotaline and killed between days 1–10
after exposure, the earliest documented change was damage
to the hepatic sinusoids; ﬁbrosis and obliteration of the terminal hepatic veins occurred as a subsequent lesion. This
articulation that toxic injury to the hepatic sinusoids was
the fundamental lesion of hepatic veno-occlusive disease
led to its being renamed sinusoidal obstruction syndrome
(SOS).30
The rat model of SOS may be summarized as follows.29,31 Following a single gavage with monocrotaline,
within 24 h–48 h there is ultrastructural evidence of
damage to hepatic sinusoidal endothelial cells (SEC), but
little clinical or histological evidence of hepatic toxicity.
By days 3–5 (early SOS), manifestations of sinusoidal
obstruction are severe, with severe centrilobular necrosis
and hemorrhage, damage to endothelial cells of the
terminal hepatic veins, subendothelial hemorrhage, and
ultrastructural evidence of extensive destruction of the
sinusoidal wall. The clinical manifestations are
hepatomegaly, ascites, and hyperbilirubinemia. By days 6–
7 (late SOS), the characteristic subendothelial and
adventitial ﬁbrosis of terminal hepatic veins becomes
evident. There is continued sinusoidal and subendothelial
hemorrhage, but gradual resolution of the ultrastructural
evidence of damage to the sinusoidal endothelial cells. By
days 8–10, SOS has resolved completely in some animals,
or persisted as a severe pattern of hepatic damage in others.
Detailed study of the ﬁrst hours after monocrotaline
exposure31 reveal that SECs become swollen, with
increased adhesion of leukocytes to the endothelium.
Red blood cells dissect beneath the endothelial cells and
into the space of Disse, separating the endothelial cells
from the underlying hepatocytes and permitting free access of blood to the parenchymal space. In contrast, blood
ﬂow in the restricted sinusoidal channel becomes sluggish.
The sinusoid is eventually obstructed by an embolism of
aggregated sinusoidal lining cells, red blood cells, and
adherent monocytes. Kupffer cells are lost along the sinusoidal lining, and are replaced with an inﬂux of circulating
phagocytic monocytes which accumulate in the injured
centrilobular area. The speciﬁc toxicity of monocrotaline
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induced by either chemical or radiation toxicity, and as a
lesion separate from Budd-Chiari syndrome and Banti
syndrome.8,9
In the late 1970's, similar histologic lesions were reported from outbreaks in India and Israel, attributed to
contamination of wheat and traditional herbal remedies
with plant toxins.10,11 The histological lesions resembled
previously described hepatic veno-occlusive lesions
described in rats poisoned with Senecio plant extracts12 or
Crotolaria.13 This form of liver toxicity was ultimately
attributed to hepatic exposure to plant pyrrolizidine alkaloids,14 establishing these plant toxins as the cause of venoocclusive disease in users of herbal teas.
Bone marrow transplantation for humans with leukemias became a therapeutic option during the 1960s. Initial
challenges to this new therapy were preservation of harvested marrow, and achieving successful marrow engraftment.15 Reports of hepatic veno-occlusive disease in
patients undergoing bone marrow transplantation emerged
in the 1970's,16 followed by numerous reports which established the following apparent risk factors: bone marrow
transplantation for malignancy, involving intense chemotherapeutic and radiation conditioning regimens; patient
age over 15 years; and in particular, abnormal pretransplant
serum levels of liver enzymes.17–19 The presence of
metastatic liver disease in patients undergoing bone
marrow transplantation for solid tumors and lymphomas
also predisposed to veno-occlusive disease.20,21 In these
initial years after recognition of veno-occlusive disease as a
complication of induction regimes prior to bone marrow
transplantation, the incidence of veno-occlusive disease varied from 21% to 25% in allogeneic graft recipients,19,21,22 to
5% in recipients of autologous marrow.20,23,24 In the four
decades since routine use of bone marrow transplantation
for solid malignancies, lymphomas and leukemias,
induction regimes and therapies have helped improve, but
not eliminate, the incidence of this condition in the
transplant population. Its incidence now is primarily in
the setting of hematopoietic stem cell transplantation, but
SOS may occur in other settings as well (Table 1).
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is that of its reactive metabolite, monocrotaline pyrrole,
which binds covalently to the actin microﬁlaments of
endothelial cells.10 The F-actin depolymerizes leading to
disassembly of the actin cytoskeleton and rounding up
of the endothelial cells. Increased expression and release
of matrix metalloproteinase-9 into the extracellular space
leads to breakdown of the extracellular matrix in the space
of Disse, permitting further dehiscence of the endothelial
cells.31
These experiments gave rise to the premise that SECs
are more susceptible to toxic injury than hepatocytes.
Key pathogenic factors include SEC glutathione depletion,
nitric oxide depletion, increased expression of matrix metalloproteinases and vascular endothelial growth factor
(VEGF), and activation of clotting factors.32 In the ﬁrst
instance, drugs leading to SOS are metabolized exclusively
by the hepatocellular cytochrome P450 systems, for which
glutathione is an antioxidant recovery mechanism. Hepatic
exposure to these drugs leads to depletion of glutathione.
Severe depletion of glutathione levels in SECs renders
them susceptible to cell death; prophylactic infusion of
glutathione or N-acetyl cysteine prevents the development
of SOS in the monocrotaline-treated rat model31; post-hoc
administration of glutathione reduces the degree of sinusoidal injury, but does not prevent it. Additional evidence
in favor of the central role of glutathione depletion includes the predisposition to SOS in humans with a glutathione S-transferase M1 (GSTM1) null genotype who are
undergoing bone marrow transplantation33 or receiving
oxaliplatin for metastatic colon cancer.34 In the second
instance, nitric oxide levels in the hepatic vein of rats
decrease during induction of SOS,35 and induction of
SOS can either be exacerbated by administration of
N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor
of nitric oxide synthase, or be mitigated by infusion of
V-YRRO/NO, a liver-selective nitric oxide donor prodrug,36
Beyond providing evidence for nitric oxide depletion in the
pathogenesis of SOS,35 a role for vasoconstriction also is
implicated, since adequate nitric oxide levels inhibit vasoconstriction of hepatic stellate cells, which invest the hepatic sinusoidal from within the space of Disse.37
Matrix metalloproteinase-9 expression increases early in
the rat monocrotaline-induced SOS model; later there is a
lower magnitude increase in matrix metalloproteinase-2.
SECs are the major source of both basal and
monocrotaline-induced enzyme expression and release.
Administration of matrix metalloproteinase inhibitors prevents the development of experimental SOS.38 This implicates degradation of the extracellular matrix within the
space of Disse as contributing to loss of endothelial cell
adhesion.
Using the rat model of monocrotaline-induced SOS,
DeLeve and associates also have demonstrated that constituitive bone marrow stem cell repair of sinusoidal endothelial cells (SEC) is critical to maintenance of the sinusoidal
334
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architecture.39 Bone marrow suppression by irradiation, by
impairing this SEC repair mechanism, may contribute to
the pathogenesis of SOS.
The role of VEGF as an angiogenic factor is less clearcut.
Iguchi et al observed increased serum levels of VEGF during development of SOS in human patients,40 leaving
open the question of whether VEGF-induced acceleration
of vasopermeability, neovascularization, and/or expression
of coagulopathic tissue factors on circulating mononuclear cells may play a role in SOS pathogenesis.32 Nakamura et al41 hypothesized that antiangiogenic agents
may protect against SOS, and chose to use sorafenib to
test this hypothesis. Sorafenib is a multiple receptor tyrosine kinase inhibitor that inhibits multiple tyrosine kinases
including the VEGF receptor-2 (VEGFR-2) and -3 (VEGFR3). Its primary use is as standard treatment for hepatocellular carcinoma and renal cell carcinoma, but it may also
have an antiﬁbrotic effect in the liver and prevent the development of portal hypertension.42,43 Nakamura treated rats
with sorafenib before induction of SOS by monocrotaline
prior to partial hepatectomy, and demonstrated signiﬁcant
suppression of the morphological features of SOS, with
signiﬁcant improvement in post-hepatectomy survival.41
While loss of endothelial cells was not completely blocked,
it did suppress degradation of extracellular matrix in
the space of Disse and uplift of the endothelial cells.
Hence, although the link to VEGF is not proven owing
to the broad inhibitory action of sorafenib on tyrosine kinases, remodeling of the extracellular matrix in the space of
Disse is demonstrated to be a contributing factor to the
dehiscence of sinusoidal endothelial cells in the development of SOS.
Recent technological advances in radiation therapy have
sparked renewed interest in understanding radiationinduced liver disease (RILD)44 Although whole-liver irradiation has generally been restricted to 30–35 Gy in standard
daily fractions of 1.8–2.0 Gy owing to risk of lethal RILD
above these levels, intensity-modulated radiation therapy,
3-dimensional conformal radiation treatment planning,
and organ and tumor motion tracking enable treatment
of liver cancer with fewer but larger dose fractions.45 This
innovation is called “hypofractionated stereotactic body
RT”. Returning to the original Cynomolgus monkey
model of RILD,26 Yannam et al44 recently conducted an
escalated dose study to examine the effect of newer hypofractionated regimes on the liver. The authors demonstrated a higher tolerance for hypofractionated radiation,
but that the characteristic histological lesions of SOS still
developed at radiation doses above 40 Gy. However, a key
additional ﬁnding was that metabolic stress on the liver,
such as glucose loading or administration of total parenteral nutrition, produced substantial additional hepatic
injury and generated hepatic failure. This points towards
radiation-induced hepatocellular injury as a key component of RILD. Although this injury may be secondary to
© 2014, INASL

inadequate blood supply to perivenous hepatocytes per se, a
broader level of injury to the parenchyma may also be operative owing to upstream impairment of sinusoidal blood
ﬂow.
In separate work, a new rodent model for oxaliplatininduced SOS has been developed,46 owing to the importance of this form of chemotherapy for advanced colorectal
cancer (vide infra). The model consisted of intra-peritoneal
administration of FOLFOX (folinic acid, 5-ﬂuorouracil,
and oxaliplatin) to C57Bl/6 mice, based on the premise
that FOLFOX induces endothelial damage and leads to a
pro-thrombotic state within the liver. This new model
may permit experimental examination of the role of oxidative stress in the pathogenesis of oxaloplatin-induced SOS,
and potential amelioration or prevention of SOS by prophylactic administration of antioxidants. This model
may also be important in exploring the role of the prothrombotic state in SOS,47 unlike the monocrotaline rodent model of SOS, in which there is no evidence of
clotting abnormalities.29
Efforts to establish a rodent model of SOS arising from
hematopoietic stem cell transplantation also have more
recently met with success, using an allogeneic transplantation model involving male C57BL/6 male mice as donors
and female BALB/c mice preconditioned with whole
body irradiation as recipients.48 This gives further opportunity for productive future studies into the pathogenesis
of SOS.

Clinical Pathogenesis of Sinusoidal Obstruction
Syndrome
Experimental models of SOS in animals permitted examination of fundamental causes of sinusoidal destruction
and vascular compromise. However, clinical investigation
of human patients affected by SOS are still required, particularly since the induction pathways vary. Through the
1980s and 1990s, SOS was a complication of induction regimes for a broad set of patients undergoing allogeneic
bone marrow transplantation. The fundamental premise
was that, while SOS developed in the days and weeks

following the actual bone marrow transplantation, it was
the marrow ablation regimes prior to transplantation
that were the actual cause of the hepatotoxicity. Accordingly, induction regimes were modiﬁed so as to reduce
the incidence of SOS.
In the past decade, SOS has become primarily an issue
with patients undergoing bone marrow stem cell transplantation for widely metastatic solid tumors, or intense neoadjuvant chemotherapy for cancer metastatic to the liver. The
reported incidence of SOS in these two patient populations
remains high, prompting continuing investigation into
pathogenesis. An example is performance of gene expression proﬁling so as to examine potential mechanisms
for oxaliplatin-induced SOS in humans (vide infra).49
A recent study reports on 98 patients undergoing preoperative chemotherapy for colorectal cancer metastatic to
the liver followed by hepatic resection.50 Of these patients,
80 received preoperative chemotherapy. SOS occurred in
39 of these patients (39.8%), with development of SOS in
patients receiving oxaliplatin-based neoadjuvant chemotherapy signiﬁcantly higher than those receiving nonoxaliplatin-based chemotherapy. Histological examination
of resected non-tumoral liver tissue showed increased
CD34 immunohistochemical reactivity in sinusoids, the
intensity of which correlated both with preoperative functional studies of indocyanine green retention, and severity
of histological SOS. These authors conclude that sinusoidal capillarization, as evidenced by CD34 expression, may
be a component of the hepatic functional deterioration
in the setting of SOS.

PATHOLOGY
SOS may exhibit acute, subacute, and chronic features,
depending upon when liver material is obtained. Unfortunately, as this disease is focal in nature, diagnostic features
may not be evident on liver biopsy. In acute disease, there is
striking centrilobular congestion, with centrilobular hepatocellular necrosis and accumulation of hemosiderin-laden
macrophages (Figure 1). The terminal hepatic venules
exhibit intimal edema, without obvious ﬁbrin deposition

Figure 1 Early histology changes of sinusoidal obstruction syndrome. (A) Post-mortem liver: low power image showing massive pericentral congestion and hemorrhagic necrosis. Masson Trichrome, 4X. (B) Liver biopsy: high power image of pericentral region, showing subtotal occlusion of terminal
hepatic venule, with entrapped erythrocytes. Hematoxylin & eosin, 400X. (C) Liver biopsy: high power image showing dilatation of sinusoids and
necrosis of hepatocytes. Terminal hepatic vein is occluded, but collagen deposition has not yet occurred. Masson trichrome, 400X.
Journal of Clinical and Experimental Hepatology | December 2014 | Vol. 4 | No. 4 | 332–346
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or thrombosis. As discussed above, SOS arises from toxic
injury to the sinusoidal endothelium.51 The cells round
up and slough off the sinusoidal wall, embolizing downstream and obstructing sinusoidal blood ﬂow. This is
accompanied by dissection of erythrocytes into the space
of Disse and downstream accumulation of cellular debris
in the terminal hepatic vein. Proliferation of perisinusoidal
stellate cells and subendothelial ﬁbroblasts in the terminal
hepatic vein follows, with deposition of extracellular matrix. Liver biopsies are almost never obtained during the acute
stage.
Over days to weeks (subacute), collagen deposition occurs in and around the affected terminal hepatic venule
(Figure 2). This leads to progressive obliteration of the
venule, which is easily identiﬁed with special stains for
either collagen or reticulin.52 Obvious centrilobular congestion
without readily identiﬁable terminal hepatic veins on hematoxylin
and eosin stain should prompt performance of connective tissue
stains to exclude SOS. With persistence of the SOS lesion
into weeks to months (chronic), dense perivenular ﬁbrosis
radiating out into the parenchyma develops. The scar tissue contains hemosiderin-laden macrophages, and terminal hepatic vein lumina cannot be identiﬁed. Notably,
congestion is minimal at this stage. There may be severe
destruction of lobular parenchyma, and rarely evolution
to cirrhosis.

FAN & CRAWFORD

When liver biopsy is performed, either in the acute stage
or during a more chronic stage, the histologic ﬁndings of
SOS may be strikingly evident (Figure 3). That being said,
the pathologist must be alert to SOS being the cause of these
ﬁndings, since failure to recognize the centrilobular venopathy may lead to misinterpretation of the histologic ﬁndings.

CLINICAL CONSIDERATIONS
Hematopoietic Stem Cell Transplantation
SOS developing after allogeneic hematopoietic stem cell
transplantation (HSCT) typically occurs within the ﬁrst
month after HSCT, although later onset has been
described.53 Conditioning regimens associated with onset
of SOS typically consist of cyclophosphamide combined
either with total body irradiation or busulfan.54
Liver disease occurs in up to 80% of patients following
hematopoietic stem cell transplantation (HSCT) for malignancies, ranging from mild and reversible elevation of
serum transaminases, to fatal hepatic failure.52 The incidence of SOS is much lower following HSCT for idiopathic
aplastic anemia, reported as 7%, but still carries a high
fatality rate (21%) if it occurs.55 SOS is part of a broader
pattern of toxic liver damage occurring following
HSCT,56 in which generalized impairment of liver function
in the immediate post-transplantation period, may be

Figure 2 Sinusoidal obstruction syndrome of longer duration, post-mortem livers. (A) Medium power image showing deposition of loose fibrous tissue
in pericentral region, with early formation of fibrous bridges to adjacent centrilobular areas. Masson trichrome, 40X. (B) Medium power image of terminal hepatic vein, showing complete loss of pericentral hepatocytes with sharp demarcation zone from viable hepatocytes in the middle of the lobule.
The lumen of the terminal hepatic vein is completely occluded, and there is extravasation of erythrocytes in the pericentral space. Masson trichrome,
100X. (C) Higher power image of terminal hepatic vein, showing intraluminal deposition of extracellular matrix, with residual lumen. Reticulin stain,
200X. (D) Low power image of post-mortem liver with SOS of longer duration, with extensive destruction of the parenchyma and central-to-central
fibrous bridging. Masson trichrome, 4X.
336
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Figure 3 Liver biopsies. (A) Biopsy from patient with acute SOS, demonstrating extensive dilatation and congestion of sinusoids, and lack of evident
terminal hepatic veins. Hematoxylin and eosin, 100X. (B) Same liver biopsy, showing terminal hepatic vein with narrowed lumen, intraluminal deposition
of extracellular matrix with entrapped erythrocytes. Masson trichrome, 100X. (C) Biopsy from patient with chronic consumption of herbal teas, showing
extensive destruction of pericentral parenchyma with deposition of fibrous tissue, inflammation, and partial obliteration of the terminal hepatic vein
lumen. Hematoxylin and eosin, 100X. (D) Liver biopsy from a different patient, also consuming herbal teas, showing inapparent terminal hepatic
vein, extensive extravasation of erythrocytes into pericentral parenchyma, and diffuse pericentral fibrosis. Masson trichrome, 100X.

further complicated by SOS in the weeks following transplantation, or nodular regenerative hyperplasia months
later.28 Although initial reports of SOS incidence were in
the 60% range,17 a more recent meta-analysis of 135 studies
performed between 1979 and 2007 place the overall mean
incidence of SOS following HSCT at 13.7% (95% conﬁdence interval = 13.3%–14.1%)57 In one report, the cumulative incidence was signiﬁcantly higher 20 years ago (1985–
1996) than in more recent years (1997–2008), attributed to
reduced-intensity conditioning regimes for HSCT, and the
reduction in use of unrelated donors for HSCT.58
Onset of SOS is characterized by painful hepatomegaly,
jaundice, weight gain, and ascites. Severe SOS is typically
associated with multiorgan failure (MOF) and high mortality rates (>80%)57–59 The sudden weight gain and the
development of hepatomegaly and tenderness typically
occur on day 0 or 1 following HSCT, or 8–10 days after
initiation of cytoreductive therapy. From the standpoint
of clinical parameters, when serum bilirubin values
exceed 15 mg/dl and weight gains approach 10–15 kg,
mortality exceeds 90%.60 While persistent severe liver
dysfunction is a harbinger of a fatal outcome, liver disease
per se is not usually the direct cause of death; most patients
succumb to septicemia, pneumonia, and bleeding and/or
multiorgan failure.57 Pretransplant hepatitis (elevation of
serum transaminases) is a risk factor for liver toxicity after
transplantation.

Criteria for a clinical diagnosis of SOS are the occurrence of at least two of the three following symptoms during the ﬁrst month after bone marrow transplantation:
jaundice, development of tender hepatomegaly and rightupper quadrant pain, ascites, and/or unexplained weight
gain.61 Serum transaminase levels may also rise substantially, but do not differentiate between potential causes
of liver injury. Recommended clinical indices for assessing
the severity of SOS are given in Table 2 (62). Given the risks
of complications, liver biopsy is usually reserved for patients in whom the diagnosis of SOS is unclear and there
is a need to exclude other diagnoses.61 Owing to the potentially severe condition of patients requiring liver biopsy, the
transjugular approach has been recommended to reduce
Table 2 Clinical Grading of Sinusoidal Obstruction
Syndrome.a
Mild

Moderate

Severe

Bilirubin, mg/dL

<5

5.1–8.0

>8.0

Liver enzymes (AST, ALT)

<3X normal

3–8X normal

>8X normal

Weight above baseline

<2%

2–5%

>5%

Serum creatinine

Normal

<2X normal

>2X normal

Clinical rate of change

Slow

Moderate

Rapid

AST, aspartate transferase. ALT, alanine transferase.
a
Per reference. 62
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the risks associated with the procedure. With the passage
of time after transplantation, liver biopsy may be increasingly necessary to sort out the diagnostic possibilities in
these patients. In these later time frames, coagulation
status may be more intact, permitting a percutaneous
approach.

Differential Diagnosis
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Diagnoses to be excluded, if possible, include: graft-versushost disease (GVHD); other causes of venous outﬂow
obstruction such as Budd-Chiari syndrome and congestive
heart failure; drug reactions, including the toxic effects of
hyperalimentation; and infections such as viral hepatitis,
fungi, and sepsis. The pathology of Budd-Chiari syndrome
features centrilobular congestion and potentially parenchymal destruction, but without the occlusion of terminal
hepatic veins seen in SOS. Drug reactions exhibit parenchymal damage with hepatocellular apoptosis, cholestasis,
and parenchymal inﬂammation. While severe SOS may
cause similar histology in its more severe stages, identiﬁcation of the terminal hepatic vein lesions is readily made in
such cases. Importantly, the clinical features of posttransplantation “drug toxicity” and the speciﬁc condition
of SOS are similar, and there is no speciﬁc management
of either condition except supportive. Hence, there is less
need to make a speciﬁc diagnosis of SOS by liver biopsy
in these unstable patients, as there is need to exclude other
potential causes of hepatic dysfunction. Lastly, patients
who undergo stem cell transplantation for nonmalignant
conditions are less likely to develop liver toxicity, as the
doses of cytoreductive therapy are generally lower than
those given for malignancy.19
Owing to the concomitant risk of post-transplant
GVHD, sirolimus has been used to reduce that risk. However, there is an increased risk of SOS after sirolimus-based
GVHD prophylaxis63 Sirolimus may act as an endothelial
toxin, and has been associated with another endothelial
injury syndrome, thrombotic microangiopathy, after
transplantation.64 Cutler et al have proposed that biomarkers of endothelial injury can be used to predict the
development of SOS following HSCT.65 These include
pre- and post-transplant measurement of circulating von
Willebrand Factor (vWF), thrombomodulin, E-selectin,
and soluble intercellular adhesion molecule-1 (sICAM-1).
Increased serum vascular endothelial growth factor
(VEGF) after HSCT also has been correlated with development of SOS.40

Cytoreductive Conditioning Prior to
Hepatectomy for Metastatic Disease
The liver is the most common site of metastatic tumor
spread, and SOS may occur in patients with metastatic solid
tumors to the liver who are given alkylating agents such as
oxaliplatin prior to surgical resection of the metastatic tu338
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mors.66 In particular, nearly half of patients with colorectal
cancer develop liver metastases during the course of their
disease.67 For patients with limited metastatic burden of
colorectal cancer in the liver, surgical resection of the hepatic tumor deposits without chemo-inductive therapy offers
the best opportunity for cure,68 with a ﬁve-year survival
rate of 40%–58%.69,70 However, 60%–70% of patients
undergoing initial curative resection suffer recurrent
disease, of whom 10%–15% may be eligible for repeated
resections.71 The remainder are relegated to chemotherapy.
For patients with initially unresectable colorectal metastatic disease, chemotherapeutic regimes can rescue a reported
12.5% by promoting tumor down-sizing and enabling
successful surgical resection of residual disease.72 Widely
utilized regimens for this latter purpose consist of a thymidylate synthase inhibitor such as 5-ﬂuorouracil, folinic acid,
or capecitabine, in combination with either oxaliplatin or
irinotecan. More recently, antibody therapy in the form of
bevacizumab or cetuximab has been included in these
regimes.73 Thus, there is a potentially large population of
patients with advanced colorectal carcinoma who will be
subjected to either adjuvant or neoadjuvant chemotherapy.
In the pediatric population, chemotherapy accompanying
hepatectomy for metastatic solid cancer such as Wilms tumor may also cause hepatic SOS.74,75
Oxaliplatin is a key agent in such regimes, and may
cause sinusoidal injury, onset of SOS, and increased
morbidity before or after hepatectomy.76–78 Histologic
evidence of high-grade lesions of SOS has been reported
to be present in 59% of patients receiving preoperative oxaliplatin treatment before hepatectomy, based on examination of the surrounding resected liver.79 The presence of
such sinusoidal injury had a detrimental effect both on
the intra- and post-operative course of patients undergoing major liver resection. In the ﬁrst instance, both intraoperative bleeding and transfusion rate were increased in
patients with high grade SOS lesions, when compared to
those with low grade SOS lesions. In the second instance,
post-operative complications were signiﬁcantly more
frequent and severe, including development of a large
amount of post-operative ascites and liver insufﬁciency.
Ironically, oxaliplatin has also been demonstrated to
induce focal hepatic SOS that can mimic metastatic liver
disease. Speciﬁcally, a 40 year old woman is described as
receiving adjuvant oxaliplatin chemotherapy for advanced
rectal cancer without clinically evident hepatic metastases.
She then developed three hypovascular tumors in the liver
which, on resection, were shown to be focal peliotic spaceoccupying lesions resulting from SOS.80
The occurrence of post-hepatectomy SOS is also associated with early tumor recurrence and decreased long-term
survival.81 Parenthetically, conditioning pre-hepatectomy
regimens for metastatic colorectal carcinoma involving irinotecan are not subject to concerns about SOS, but there is
risk of chemotherapy-associated steatohepatitis.82
© 2014, INASL

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY

Radiation-Induced Liver Disease
Radiation therapy (RT) without chemotherapy or hepatectomy remains as a central approach for treatment of cancer
metastatic to the liver, and host conditioning for bone
marrow transplantation. Considered separately from the
combined chemoradiation regimes for stem cell transplantation, the development of radiation-induced liver disease
(RILD) limits the amount of irradiation that can be given,
and hence, the potential efﬁcacy of treatment. Patients
with RILD typically present with fatigue, weight gain, hepatomegaly, ascites, and an isolated elevation in alkaline
phosphatase in months following hepatic RT.87 Liver biopsy reveals the characteristic features of SOS affecting terminal and sublobular hepatic veins.17
RILD is a severe complication of RT. In patients who do
not succumb to this condition, liver healing occurs over
several months as the vascular congestion resolves.7 Hepatic architecture remains distorted, however, with persistent
ﬁbrosis of terminal hepatic veins and the residua of parenchymal destruction throughout the centrilobular region.87

Chemotherapy for Acute Myeloid Leukemia
A singular example of SOS occurring in the setting of intensive cytotoxic chemotherapy is the use of MylotargÒ (gemtuzumab ozogamicin, GO) for acute myeloid leukemia
(AML)88 GO is composed of a humanized conjugated antibody carrier linked to a potent antitumor antibiotic (calicheamicin). It targets the CD33 antigen expressed on the
surface of AML cells, which is relatively absent from nonhematopoietic tissues and primitive hematopoietic stem
cells. The incidence of SOS in this population of GOtreated patients is reported as 9.1%.89 Although the 6month mortality rate in this population of SOS-affected

patients was high (68%), three quarters of the deaths were
due to progression of the AML. Overall risk of death
from SOS and multiorgan failure was 2.7%.

Liver Transplantation
SOS as a cause of liver graft dysfunction after liver transplantation is rare, but has a poor prognosis.90 This is to be
distinguished from post-transplant perivenulitis, as part
of graft rejection.91 If present, SOS is more likely to occur
in living-related transplant grafts92 or in patients receiving
azothiaprine as part of their immunosuppressive regime.93
Better optimization of immunosuppression is suggested
as an approach to reduce the incidence of this rare event.93

Exposure to Herbal Toxins
The use of hepatotoxic herbal remedies by humans has
recently been extensively reviewed.94 An estimated 500
herbal products are distributed worldwide, and are represented as harmless healthy products without side effects95,96 Over 60% of patients in the U.S. being seen by a
physician report use of herbal remedies.97 Because herbal
products are considered dietary supplements in many
countries including the U.S., proof of efﬁcacy and safety
does not have to be provided by the manufacturer. However, hepatotoxicity has been widely reported, up-to-andincluding development of SOS. It has been estimated
that more than 6000 plant species contain pyrrolizidine alkalioids with different chemical structures.98
One of the well-known herbs containing pyrrolizidine
alkaloids is Symphytum ofﬁcinale, commonly known as
comfrey.99 This herb has been used as an external remedy
for bone fractures, joint inﬂammation, and wound healing,
and internally for gastroduodenal ulcers and gastritis.100
Comfrey-induced injury involves ﬁbrous obliteration and
destruction of hepatic veins, leading to cirrhosis.101,102
However, hepatotoxicity, including SOS, acute or chronic
hepatitis, cholestasis, hepatic necrosis or ﬁbrosis,
cirrhosis, and outright liver failure, can occur with a
much broader array of herbal products,103 owing to variability in what plant components have been used, storage
conditions for the plant products, mislabeling or misidentiﬁcation of the plant, and outright contaminations,104,105
Even Echinacea, widely touted as being completely free of
toxicities, is known to contain pyrrolizidine alkaloids and
may induce hepatotoxicity.106
Clinical presentation of hepatotoxicity arising in the
setting of herbal product use is non-speciﬁc, involving fatigue, loss of appetite, and potentially jaundice. Hepatomegaly, ascites, and hyperbilirubinemia may be evident.
Liver enzymes may be elevated in either a hepatitic, cholestatic, or combined pattern. Similar to onset of SOS in the
post stem cell transplantation setting (vide infra), there are
no symptoms or laboratory ﬁndings that speciﬁcally implicate SOS.
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Preoperative laboratory indices designed to predict liver
ﬁbrosis in patients with hepatitis C virus-related liver disease involve such calculations as aspartate aminotransferase (AST) to platelet ratio index (APRI) and ﬁbrosis
scoring systems.83,84 Recent application of these clinical
parameters to patients undergoing oxiplatin-based induction chemotherapy for metastatic colorectal carcinoma
suggest that the APRI score, along with a low preoperative
platelet count, may be reliable predictors of SOS severity
following hepatectomy.79 In the post-hepatectomy timeframe, measurement of circulating Hyaluronic Acid as a
measure of endothelial function also has been advocated
as a clinical marker of risk for SOS.85 More recently, monitoring of post-hepatectomy splenic volume by imaging
methods has been found to be a useful predictor of risk
for the development of SOS.69 Lastly, polymorphisms in
the ATP7B gene, which encodes for a transmembrane
drug transporter, have been identiﬁed which may explain
varying susceptibility to SOS among patients following
oxaliplatin-based chemotherapy.86
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The presence of this form of liver injury requires liver biopsy, and attentiveness to this possibility in examining the
biopsy tissue. The presence of perivenular necrosis, endophlebitis and ﬁbrotic alterations of terminal and sublobular hepatic veins are consistent with SOS.107 More severe chronic exposure to the hepatotoxins in comfrey can
manifest clinically in hepatomegaly and ascites, with SOS
again conﬁrmed by liver biopsy,108,109 even in the very
young child given comfrey tea.110 However, histological examination of liver tissue may be difﬁcult to perform owing
to ascites and coagulopathy. In such instances, diagnosis of
SOS may have to rely on clinical features and a retrospective
history of drug or herb exposure. Recently, development of
an ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) assay for identiﬁcation of pyrroleprotein adducts in peripheral blood may prove to be a useful supplement to conventional diagnostic methods.111
With either mild or moderate cases of SOS, removal of
the offending agent may offer good prospects for clinical
recovery. In the most severe cases of herbal toxin-induced
SOS in adults, hepatic failure may ensue. Notably, a fatal
case of SOS has been reported in the preterm infant born
of a mother consuming herbal teas.102
Because botanicals are self-prescribed, self-administered, and widely available, they are difﬁcult to control
and difﬁcult to document.94 Unspeciﬁed mixed formulations are common. The point should be made that severe
hepatotoxicity, including SOS, may be quite rare, given
the massive use of herbal products and the relative infrequency of severe clinical presentations.107 Nevertheless,
healthcare providers are well-advised to obtain accurate information about their patients' use of herbal remedies, and
to ensure that they are well educated about their potential
hepatotoxicities.

Veno-occlusive Disease with Immunodeﬁciency
In 1976, Mellis and Bale described ﬁve infants from three
families who died between the ages of 2 and 7 months
with veno-occlusive disease of the liver.112 All infants had
some evidence of immune deﬁciency, including hypogammaglobulinemia, multiple infections including infection
with Pneumocystic jerovici, enteroviral infections, and/or
mucocutaneous candidiasis, and lymphoid tissues devoid
of germinal centers and mature plasma cells. An additional
19 cases of what is now termed autosomal recessive hepatic
veno-occlusive disease with immunodeﬁciency syndrome (VODI)
have been identiﬁed over the ensuing years. VODI is associated with an 85% mortality if unrecognized and untreated with intravenous immunoglobulin and P. jerovici
prophylaxis. The lack of hepatic veno-occlusive disease in
other forms of inherited immunodeﬁciency suggest that
this is a primary feature of VODI.
In 2006, Roscioli et al113 described mutations in the promyelocytic leukemia protein (PML) nuclear body protein
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Sp110 in six children from ﬁve families of Lebanese
ethnicity, who met the clinical criteria for VODI. The immunodeﬁciency consisted of a combined T and B cell
immunodeﬁciency. The B cell immunodeﬁciency was characterized by evolving severe hypogammaglobulinemia,
absent memory (CD19+ CD27+ IgD ) B cells and tonsillar
lymph nodes, and circulating CD19+ B cell numbers and
percentages within the normal range. The T cell immunodeﬁciency was characterized by reduced numbers of memory (CD4+ CD45RO+ CD27 ) T cells, and low or reduced
intracellular T cell cytokine expression after antigen stimulation. SP110 is an immunoregulatory gene expressed in
T and B lymphocytes within lymph nodes, spleen and liver.
The affected infants in four of the families had a homozygous single-base deletion, 642delC (P214PfsX15) in exon 5.
There were no living affected individuals in the ﬁfth family,
but the consanguineous parents and unaffected children
of these families exhibited a heterozygous single-base deletion, 40delC (Q14SfsX25) in exon 2 of SP110. The central
role of the SP110 mutation in VODI, along with identiﬁcation of novel mutations and key clinical and immunological features, has been conﬁrmed in an extensive
additional study.114 This and a limited number of other
studies have shown that early disease recognition and management (e.g., immunoglobulin replacement therapy and
trimethoprim-sulfamethoxazole prophylaxis) can improve
the dismal mortality rates.115 HSCT, when carried out
before disease onset, can be curative. In one publication,
antenatal diagnosis was possible for a family with a known
risk of this disease.116
Interestingly, SP110 is a single-copy gene in humans.
However, in all inbred strains of laboratory mice, it is
part of a rearranged and ampliﬁed genomic region containing approximately 60–2000 copies of Sp110 and 20
adjacent genes.117 It therefore has not been possible to produce a genetic knockout model of Sp110 for study of the
tissue pathobiology of this syndrome. Thus, despite the
potential unique opportunity to gain insights from
SP110 mutation into the immunopathogenesis of hepatic
veno-occlusive disease (SOS), the evolution of the hepatic
vascular lesions in VODI has not been elucidated.

THERAPY AND PREVENTION
Supportive Measures
Current management of SOS consists primarily of supportive care, with a focus toward ﬂuid management,
adequate oxygenation and transfusional support to minimize ischemic liver injury, and avoidance of hepato/nephrotoxins.118,119 Speciﬁcally, patients with mild SOS, as
deﬁned by clinical indicators (Table 2) can be observed.62
Patients with evidence of moderate SOS should be treated
expectantly with mild diuretics. This helps mitigate against
ﬂuid overload, while preserving renal blood ﬂow and so as
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Deﬁbrotide
The investigational drug Deﬁbrotide (DF) has shown the
most promising results in clinical trials to date. The use
of Deﬁbrotide (DF) for the treatment of SOS/VOD is supported by a large number of clinical trials showing that DF
improves both complete response and survival. Richardson
et al119 ﬁrst reported on 19 patients with SOS and multiorgan failure who had received Deﬁbrotide for the management of severe SOS in the United States. The efﬁcacy of
Deﬁbrotide (DF) for the treatment showed complete resolution of SOS in 8 patients (42%), 6 of who survived for
longer than 100 days with no signiﬁcant bleeding
observed.120 A number of trials have subsequently
conﬁrmed the efﬁcacy of DF in this setting, including a
similar European multicenter compassionate-use study,
which treated 40 patients and demonstrated a 55% complete response (CR) rate, with 43% patients alive after 100
days.121 Importantly, the US Food and Drug Administration permitted access to DF in the United States through
an investigational new drug compassionate-use treatment
protocol in December 2007. An interim analysis of 269 patients enrolled between December 2007 and March 2011 at
67 US centers revealed that 32% of patients achieved a CR
at day-100 post-HSCT, with an overall day-100 survival of
50%.122 To date, DF has been used in more than 240 transplantation centers across 33 countries as a result of a large
compassionate-use program and the ongoing named patient programs.
Based on an overall experience in more than 1800 patients, DF continues to demonstrate remarkable safety
and tolerability despite a very ill patient population, with
manageable toxicities and low rates of attributable hemorrhage.59 In a study from Spain of 845 patients over 24 years
receiving allogeneic HSCT, a total of 117 patients developed SOS.57 Overall mortality from SOS decreased, from
a reported 22% in 1997 to 14% in 2008, despite no change
in clinical severity of the SOS.57 For those patients with
severe SOS and multiorgan failure, only 2 of 8 (25%) of
patients receiving deﬁbrotide died, versus 14 of 18 (78%)
for those severely ill patients receiving other treatments.

Tissue-Plasminogen Activator (t-PA)
Anticoagulation and thrombolytic therapies using tissueplasminogen activator (t-PA) have been used, but are
reported to be ineffective and are associated with signiﬁcant bleeding complications.59,123 The use of tissue
plasminogen activator with or without heparin has been
evaluated in a number of studies and small case series.

However, results have generally been disappointing;
although about one-third of patients show improvement
in their SOS with thrombolytic therapy, life-threatening
hemorrhages are common, and no survival advantage is
apparent.118
For pediatric patients developing SOS after chemotherapy and hepatectomy, careful supportive measures
and anti-ﬁbrinolytic drugs are the standard treatment,74,75
In one report, two patients with life-threatening SOS who
failed to respond to the standard therapeutic approach
were successfully treated with non-activated protein C supplementation.124

Methylprednisolone
High dose methylprednisolone has also been used in the
treatment of SOS. Some studies reported that response
was deﬁned as a reduction in the total serum bilirubin by
50% or more within 10 d of initiation of corticosteroids.
Sixty-three percent of patients responded and 28/48
(58%) were alive at 100 days from transplant.61 A recent pediatric retrospective study described by Myers et al, 2013, 9
patients who received methylprednisolone.125 Eight of
these patients had multi-organ failure secondary to SOS.
Response was deﬁned as a 50% reduction in bilirubin level
by 10 days after the commencement of therapy. Six patients responded to treatment. Four patients also received
treatment with deﬁbrotide. Overall survival was 78%.125
Methylprednisolone may be considered for the use in the
treatment of SOS with the appropriate caveats of caution
regarding infection.

TIPS
Transjugular intrahepatic portosystemic shunt (TIPS)
insertion has been used to decompress the portal circulation, and relieve ascites in some patients with hepatic
SOS, but in some others this procedure has been shown
to worsen the process and did not improve the
outcome.126–128

Liver Transplantation
Liver transplantation has been reported as a treatment for
SOS.129–131 However, it should be considered only in
patients with severe liver failure who are expected to have
a good outcome in the absence of liver disease, and those
who have undergone bone marrow transplantation for
benign disease. Liver transplantation is usually contraindicated when malignancy is present because of the
high rates of recurrence.

Prevention
Holding to the adage that “an ounce of prevention is worth
a pound of cure”, prevention remains the primary tool in
the clinician's arsenal for managing SOS in the HSCT
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to avoid prerenal azotemia and potential hepatorenal syndrome. If ascites occurs, paracentesis may be required.
However, the amount of ascites removed should be modest,
in the range of 1 liter per day, so as to not harm renal blood
ﬂow.62 Patients with severe SOS require treatment.
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population.62 The ﬁrst step is identiﬁcation of patients at
higher risk for developing SOS, namely those with preexisting liver injury or global systemic inﬂammation.132
These include patients with pre-existing viral hepatitis,
alcoholic hepatitis, or steatohepatitis, or other causes of
elevated liver enzymes, heavy exposure to hepatotoxic
agents, a history of infection and long antibiotic exposure,
or patients with reduced diffusing capacity of the lung.62
Risk factors arising directly from HSCT include those
receiving high doses of total body irradiation (TBI), cyclophosphamide exposure and dosage, oral busulfan use, and
exposure to other hepatotoxic medications.133–137 The
reported incidence of SOS following allogeneic
hematopoietic stem cell transplantation has diminished
and the outcome improved over the last decade.138 This
has been attributed to reduced-intensity conditioning
HSCT (RIC-HSCT) for patients myeloablative-HSCT
from unrelated donors.
Patients identiﬁed as being at higher risk for SOS
should be considered for prophylaxis. Ursodeoxycholic
acid (ursodiol) beginning two weeks before transplantation is commonly used. That being said, the evidence as
to whether early prophylactic use of ursodeoxycholic acid
(ursodiol) reduces the incidence of SOS in the HSCT population is equivocal.139–142 Ursodeoxycholic acid is a
naturally occurring hydrophilic bile acid that functions
to reduce the fraction of potentially hepatotoxic
hydrophobic bile acids in the hepatobiliary system. It can
also have modulating effects on cytokine expression and
reduce inﬂammation.143 Institution of low-dose heparin
prophylaxis is a more aggressive approach, as it requires
an infusion regime, and the evidence for efﬁcacy of this
prophylaxis also is equivocal.144–146 Glutamine
supplementation, use of peripheral blood progenitor
cells as opposed to those derived from the bone marrow,
and T-cell depletion as prophylaxis against graft-versushost disease have been reported as having reduced incidence of SOS.147,148 In the pediatric population
undergoing HSCT, a prophylactic regime of enoxaparin
or ursodeoxycholic acid and vitamin E has been of
potential value.149
Lastly, aggressive ﬂuid management and control of ﬂuid
balance during the course of HSCT are essential. Although
not proven to prevent SOS, successful ﬂuid management
can reduce hepatic congestion and potentially eliminate a
source of hepatic insult. Inputs, outputs, and weight are
strictly recorded daily, with aggressive diuresis to maintain
euvolemia.
In the population of patients with metastatic colorectal
carcinoma, the addition of bevacizumab to oxaliplatinbased chemotherapy can attenuate the incidence and
severity of SOS.40,150,151 Bevacizumab (Bmab) is a
monoclonal humanized antibody directed against VEGF,
and is an approved drug for ﬁrst-line treatment of metastatic colorectal cancer, but only as part of combination
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chemotherapy.152 It is gratifying that this drug may also
help prevent one of the life-limiting complications of one
of the companion chemotherapeutic agents, oxaliplatin.
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